OSL OncoSil Medical Limited
Healthcare · Medical Devices
· website
$1.34
52wk 0.37 – 2.09
Overall
—
Value
—
Growth
—
Health
—
Quality
—
Momentum
—
Dividend
—
Price
About OncoSil Medical Limited
OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company's lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.
Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$41.55M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.94
Dividend yield
—
Payout ratio
0.0%
Beta
1.23
EV / EBITDA
-1.47
Price / Book
6.59
ROE
-208.4%
Operating margin
-144.0%
Net margin
0.0%
Total cash
$2.85M
Total debt
$42,469
Current ratio
2.05
Debt / Equity
0.01
Free cash flow
$-8.53M
Avg volume
240,454
Latest annual results
(FY ending 30 Jun 2025)
- Revenue$1.17M
- Gross profit-$1.08M
- Operating income-$15.49M
- Net income-$15.10M
- Diluted EPS-1.37
- Free cash flow-$12.08M
- Net debt-$5.04M